Checkpoint Therapeutics, Inc.

India’s top-ranked drug maker Sun Pharmaceutical Industries has signaled growing ambitions in the oncology-dermatological segment, snapping up the US immunotherapy and targeted oncology company Checkp

US Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan

In an unscripted moment of synchronicity, the complete response letter for linvoseltamab announced by Regeneron Pharmaceuticals, Inc. on 20 August exemplified the findings of a US Food and Drug Admi

A string of complete response letters from the US FDA clouded the 2024 outlook for novel cancer therapies, but a productive pipeline is carrying enough candidates towards second half user fee goal dat